SeqOne has entered into a definitive agreement to acquire Congenica, the UK genomics company spun out of the Wellcome Sanger Institute. The combined organisation will focus on clinical genomics software, serving 160+ laboratories across 30+ countries with AI-driven analysis and clinical interpretation.
SeqOne provides an AI-enabled platform for next-generation sequencing (NGS) analysis and clinical decision support across oncology, rare and inherited disease, and infectious disease. Congenica contributes established decision-support technology and clinical interpretation services, with experience across NHS Genomics Laboratory Hubs and national programmes including Genomics England and the Hong Kong Genome Program.
Addressing the interpretation bottleneck
As sequencing costs fall and data volumes surge, interpretation at scale is a major barrier to delivering personalised medicine. SeqOne states that highly intelligent software is needed to turn complex genomic data into rapid, actionable insights—accelerating rare disease diagnosis and enabling more precise cancer care.
Comments from leadership
“The rapid pace of personalised medicine demands continuous investment in software innovation and deep specialisation. By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project.”
Martin Dubuc, CEO, SeqOne
Momentum and scale
SeqOne reports recent organic growth, expansion from three to 30+ countries in the past year, and the earlier acquisition of Life & Soft to extend capabilities in multi-omics and virology, supported by a €20 million funding round. According to the company, the combined entity aims to:
- Serve 160+ customer laboratories across 30+ countries
- Employ 125+ people
- Enable 200,000+ patient genomic analyses in 2025 (around three times 2024 volume)
Customer continuity and UK presence
SeqOne says all Congenica customers will continue to receive service and support, with access to an expanded product portfolio. The company intends to maintain a meaningful UK presence, including at the Wellcome Sanger Institute.
Third-party perspective
“Congenica has been an instrumental partner to Genomics England, particularly in advancing rare disease diagnosis through their robust platform for clinical whole genome analysis. We look forward to continuing this important work with the combined expertise of the SeqOne team to deliver benefits for patients.”
Dr Richard Scott, Chief Executive Officer, Genomics England
Deal terms
The financial terms have not been disclosed.
